🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hear ye hear ye! FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors | FDA Her2 3+ 👉🔥🎯If it’s a marker, it’s a pan cancer marker: Tissue is not the issue fda.gov/drugs/resource…

A major challenge that drug developers face in the development of rare cancer medicines is the accessibility of biomarker testing. Jim Palma of TargetCancer Fdn emphasizes that education is key not just for patients but also providers. #WorldOrphanUSA

Proud to have had our abstract accepted for presentation at the upcoming ASCO Annual Meeting - Jim Palma TargetCancer Fdn Questrom School of Business, Boston University ASCO oncodaily.com/67350.html #ASCO24 #Cancer #OncoDaily #Oncology #TargetCancerFoundation

Please join us at #ASCO24 on Saturday June 1 between 9:00am - 12:00pm to view our poster and learn more about TRACK, our decentralized, patient-driven, precision medicine clinical trial in #rarecancers. Learn more here: lnkd.in/ep6SuScZ

Honored to be PI of this study. THE national precision genomics trial for rare cancers. Jim Palma/TargetCancer Foundation made it possible for patients to be on trial in their own homes. A home-run trial Big thanks to Drs Adashek, Nikanjam, Kato, and Subbiah, and amazing team

@jacobadashek TargetCancer Fdn Vivek Subbiah, MD Jason Sicklick Arturo LoAIza-Bonilla, MD MSEd Ivy Riano, M.D. Fernando Diaz, MD Foundation Medicine Charu Aggarwal, MD, MPH, FASCO Yüksel Ürün Rare Cancers Europe What a fine crew— all rising for TargetCancer and patients with rare cancers

The TargetCancer Fdn Think Tank on Advancing Precision Medicine in Rare Cancers returns to Boston on November 20, 2024! Agenda and registration details are coming soon, and you can learn more about previous Think Tanks by visiting our website. #rarecancer targetcancer.org/research/think…

Registration is now open for the TargetCancer Fdn Think Tank on Advancing Precision Medicine in Rare Cancers! Please join us in Boston on November 20 for this interactive meeting focused driving #rarecancer treatment development forward. Learn more here: targetcancerfoundation.org/thinktank

Join TCF TargetCancer Fdn at 1pm ET on Sept 30 for a special #RareCancerDay webinar! Dr. Mina Nikanjam and rare cancer patient advocate Dana Deighton will discuss the importance of patients and practitioners working together when navigating a #RareCancer diagnosis!

Today is #RareCancerDay! Please join us in raising critical awareness of the unique challenges of rare cancers- learn how to get involved and download rare cancer infographics at our website: targetcancer.org/events/rare-ca…

Starting at 1:00 pm ET- Patients and Practitioners as Partners: Initial Steps for Navigating a Rare Cancer Diagnosis. Learn more and register for this #RareCancerDay Lunch and Learn Webinar Here: us02web.zoom.us/webinar/regist…

⭐ Today is RARE Cancer Day ⭐ ⭐ In our interconnected world, the voices and experiences of patients are more critical than ever in driving forward research and finding innovative solutions for rare diseases. By leveraging the power of social media, we are unraveling the

Great news- A bipartisan Congressional resolution was introduced recognizing 9/30 as Rare Cancer Day! Thanks to Reps. Rep. Mike Kelly, Rep. Brian Fitzpatrick 🇺🇸, Rep. Debbie Wasserman Schultz, Rep. Derek Kilmer, and Rep. Debbie Dingell for recognizing this day of awareness for #rarecancer. kelly.house.gov/media/press-re…

I love this meeting. Engaged participants. Moving the field forward

What an important conversation, "Bringing Research to Patients to Be More Inclusive," at this year's #NORDSummit. This is core to NORD's mission. Thank you to panelists Jim Palma of TargetCancer Fdn, a NORD Board Member, as well as Dr. Joni Rutter, Director of NCATS,

#NORDSummit: A panel of experts explored how inclusivity in rare disease clinical research can be improved by bringing trials to where patients live, work, and receive medical care. Read more here: bit.ly/3C4YLv0 National Organization for Rare Disorders (NORD) TargetCancer Fdn #ClinicalTrials

⭐️Such a delight to be back in Boston for the TargetCancer Fdn “Think Tank on advancing #PrecisionMedicine in #RareCancers, 2024”. Always a pleasure to start the morning with Razelle Kurzrock, MD & Wafik S. El-Deiry, MD, PhD, FACP ! OncoAlert

🌟 Incredible Panel Discussion with thought leaders from FDA & academia at the Target Cancer Foundation Think Tank in Boston! 🌟TargetCancer Fdn Had the privilege of engaging in a thought-provoking panel discussion with the US FDA Chief, Oncology Branch, CBER, Dr. Peter Bross

🚨Hot off the press! 🌟 We're thrilled to announce the publication of our article in the ASCO Educational Handbook 👉"Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras." 🦓 just in time for AACR & ASCO meetings! Read it for FREE online now!

🚨 New from our lab! Huge congrats to my amazing colleague and friend Vindhya Vijay —so proud of this work! A powerful resource for the cholangio field combining multi-omics and CRISPR screens across 63 biliary tract cancer (BTC) cell lines. Check it out! TargetCancer Fdn Cholangiocarcinoma Foundation